Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ECHELON-2
- Sponsors Seagen; Seattle Genetics; Takeda
- 12 Dec 2023 Results of exploratory analysis assessing interim PET4 Response As an Independent Predictor of Long-Term Outcomes assessing presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Dec 2021 Primary endpoint has not been met median PFs in >60 asper result published in the Annals of Oncology
- 15 Dec 2021 Results assessing exploratory analyses in prespecified subgroups based on age, gender, and histology to supplement the data from the full 5-year analysispublished in the Annals of Oncology